Table 2.
Comparison between patients pCR and non-pCR
| Parameters | pCR | non-pCR | P value |
|---|---|---|---|
| (n = 232) | (n = 815) | ||
| Age (years) | 0.493 | ||
| ≦50 | 132 (23.0%) | 443 (77.0%) | |
| > 50 | 100 (21.2%) | 372 (78.8%) | |
| Clinical T stage | < 0.0001 | ||
| T1 | 17 (42.5%) | 23 (57.5%) | |
| T2 | 149 (25.6%) | 433 (74.4%) | |
| T3 | 39 (19.0%) | 166 (81.0%) | |
| T4 | 27 (12.3%) | 193 (87.7%) | |
| Clinical lymph node status | < 0.0001 | ||
| N0 | 19 (24.1%) | 60 (75.9%) | |
| N1 | 164 (30.2%) | 379 (69.8%) | |
| N2 | 49 (11.5%) | 376 (88.5%) | |
| SBR grade | < 0.0001 | ||
| 1 | 4 (5.2%) | 73 (94.8%) | |
| 2 | 51 (12.6%) | 354 (87.4%) | |
| 3 | 110 (23.6%) | 356 (76.4%) | |
| Unknown | 67 (67.7%) | 32 (32.3%) | |
| ER status | < 0.0001 | ||
| Negative | 144 (32.9%) | 269 (65.1%) | |
| Positive | 88 (13.9%) | 546 (86.1%) | |
| PR status | < 0.0001 | ||
| Negative | 172 (33.1%) | 348 (66.9%) | |
| Positive | 60 (11.4%) | 467 (88.6%) | |
| HER2 status | < 0.0001 | ||
| Negative | 78 (13.4%) | 503 (86.6%) | |
| Positive | 154 (33.0%) | 312 (67.0%) | |
| Subtype | < 0.0001 | ||
| HR + /HER2− | 27 (6.4%) | 392 (93.6%) | |
| HR + /HER2 + | 66 (27.8%) | 171 (72.2%) | |
| HR−/HER2 + | 88 (38.4%) | 141 (61.6%) | |
| HR−/HER2− | 51 (31.5%) | 111 (68.5%) | |
ER estrogen receptor, HR hormone receptor, HER-2 human epidermal growth factor receptor 2, pCR pathological complete response